• +1-646-491-9876
    • +91-20-67278686

    Search

    Growth/Differentiation Factor 8-Pipeline Review H2 2017

    Growth/Differentiation Factor 8-Pipeline Review H2 2017

    • Report Code ID: RW00011060480
    • Category Life Sciences
    • No. of Pages 66
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Pipeline Review, H2 2017

    Summary

    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Myostatin also known as growth differentiation factor 8 or GDF-8 is a myokine a protein produced and released by myocytes. This protein is part of the transforming growth factor beta (TGFβ) superfamily. Myostatin is found almost in muscles used for movement, where it is active both before and after birth. This protein normally restrains muscle growth, ensuring that muscles do not grow too large.

    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) pipeline Target constitutes close to 13 molecules. Out of which approximately 13 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 1 and 7 respectively. Report covers products from therapy areas Musculoskeletal Disorders, Genetic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders, Metabolic Disorders and Oncology which include indications Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis, Muscular Dystrophy, Sarcopenia, Anemia, Becker Muscular Dystrophy, Charcot-Marie-Tooth Disease Type I, Crohn's Disease (Regional Enteritis), Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Inclusion Body Myositis (IBM), Insulin Resistance, Muscle Atrophy, Myelodysplastic Syndrome, Myelofibrosis, Sickle Cell Disease, Spinal Muscular Atrophy (SMA) and Thalassemia.

    The latest report GrowthDifferentiation Factor 8-Pipeline Review, H2 2017, outlays comprehensive information on the Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
    -The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects
    -The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Overview 7
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Therapeutics Development 8
    Products under Development by Stage of Development 8
    Products under Development by Therapy Area 9
    Products under Development by Indication 10
    Products under Development by Companies 11
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Therapeutics Assessment 14
    Assessment by Mechanism of Action 14
    Assessment by Route of Administration 15
    Assessment by Molecule Type 17
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Companies Involved in Therapeutics Development 19
    Acceleron Pharma Inc 19
    Amgen Inc 19
    Bioleaders Corp 20
    F. Hoffmann-La Roche Ltd 20
    Pfizer Inc 21
    Regeneron Pharmaceuticals Inc 21
    Sarepta Therapeutics Inc 22
    Scholar Rock Inc 22
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Drug Profiles 23
    ACE-083-Drug Profile 23
    Product Description 23
    Mechanism Of Action 23
    R&D Progress 23
    ACE-2494-Drug Profile 26
    Product Description 26
    Mechanism Of Action 26
    R&D Progress 26
    ACE-2798-Drug Profile 27
    Product Description 27
    Mechanism Of Action 27
    R&D Progress 27
    Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD-Drug Profile 28
    Product Description 28
    Mechanism Of Action 28
    R&D Progress 28
    ATA-842-Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    BLS-ILB-MD1-Drug Profile 30
    Product Description 30
    Mechanism Of Action 30
    R&D Progress 30
    domagrozumab-Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    luspatercept-Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    OSX-200-Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    REGN-2477 + trevogrumab-Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    RG-6206-Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    SRK-015-Drug Profile 46
    Product Description 46
    Mechanism Of Action 46
    R&D Progress 46
    trevogrumab-Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Dormant Products 50
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Discontinued Products 51
    Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)-Product Development Milestones 52
    Featured News & Press Releases 52
    Aug 01, 2017: Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease 52
    Jul 10, 2017: Scholar Rock and the Miami Project to Cure Paralysis Present Preclinical Data Demonstrating Therapeutic Potential of SRK-015 in Spinal Cord Injury at 35th Annual National Neurotrauma Symposium 52
    Jun 28, 2017: Scholar Rock to Develop SRK-015 to Improve Muscle Function in Patients with Spinal Muscular Atrophy 53
    Jun 23, 2017: Acceleron Provides Updated Results from Ongoing Phase 2 Study of Luspatercept in Myelodysplastic Syndromes at the 22nd Congress of the European Hematology Association 54
    Jun 23, 2017: Acceleron Provides Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia at the 22nd Congress of the European Hematology Association 55
    Jun 01, 2017: Celgene and Acceleron Complete Target Enrollment in the MEDALIST and BELIEVE Phase 3 Studies of Luspatercept in Myelodysplastic Syndromes and Beta-Thalassemia 57
    May 30, 2017: Pfizer Completes Enrollment of Phase 2 Study of Domagrozumab (PF-06252616) in Duchenne Muscular Dystrophy 58
    May 18, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association 58
    May 06, 2017: Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes 59
    Apr 27, 2017: Acceleron Provides Clinical Development Updates on Luspatercept Program 60
    Apr 06, 2017: Acceleron Announces Clinical Presentations on Luspatercept at the 14th International Symposium on Myelodysplastic Syndromes 61
    Mar 16, 2017: Acceleron Announces Plans to Initiate a Phase 2 Trial of ACE-083 in Charcot-Marie-Tooth Neuromuscular Disease and Host Educational Webinar 61
    Dec 22, 2016: Acceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy 62
    Dec 05, 2016: Acceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology 62
    Dec 04, 2016: Acceleron and Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the 58th Annual Meeting of the American Society of Hematology 63
    Appendix 65
    Methodology 65
    Coverage 65
    Secondary Research 65
    Primary Research 65
    Expert Panel Validation 65
    Contact Us 65
    Disclaimer 66

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 8
    Number of Products under Development by Therapy Areas, H2 2017 9
    Number of Products under Development by Indication, H2 2017 10
    Number of Products under Development by Companies, H2 2017 11
    Products under Development by Companies, H2 2017 12
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13
    Number of Products by Stage and Mechanism of Actions, H2 2017 14
    Number of Products by Stage and Route of Administration, H2 2017 16
    Number of Products by Stage and Molecule Type, H2 2017 18
    Pipeline by Acceleron Pharma Inc, H2 2017 19
    Pipeline by Amgen Inc, H2 2017 20
    Pipeline by Bioleaders Corp, H2 2017 20
    Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 20
    Pipeline by Pfizer Inc, H2 2017 21
    Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 21
    Pipeline by Sarepta Therapeutics Inc, H2 2017 22
    Pipeline by Scholar Rock Inc, H2 2017 22
    Dormant Projects, H2 2017 50
    Discontinued Products, H2 2017 51

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 8
    Number of Products under Development by Therapy Areas, H2 2017 9
    Number of Products under Development by Top 10 Indications, H2 2017 10
    Number of Products by Stage and Mechanism of Actions, H2 2017 14
    Number of Products by Routes of Administration, H2 2017 15
    Number of Products by Stage and Routes of Administration, H2 2017 15
    Number of Products by Molecule Types, H2 2017 17
    Number of Products by Stage and Molecule Types, H2 2017 17
    Acceleron Pharma Inc
    Amgen Inc
    Bioleaders Corp
    F. Hoffmann-La Roche Ltd
    Pfizer Inc
    Regeneron Pharmaceuticals Inc
    Sarepta Therapeutics Inc
    Scholar Rock Inc

    Request for Sample

    Report Url http://www.reportsweb.com//growth-differentiation-factor-8-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//growth-differentiation-factor-8-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//growth-differentiation-factor-8-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments